

Submit a Manuscript: https://www.f6publishing.com

World J Diabetes 2025 July 15; 16(7): 104789

DOI: 10.4239/wjd.v16.i7.104789 ISSN 1948-9358 (online)

ORIGINAL ARTICLE

# **Retrospective Study**

# Predictive model and risk analysis for outcomes in diabetic foot ulcer using eXtreme Gradient Boosting algorithm and SHapley Additive exPlanation

Lei Gao, Zi-Xuan Liu, Jiang-Ning Wang

**Specialty type:** Endocrinology and metabolism

#### Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

#### Peer-review report's classification

**Scientific Quality:** Grade B, Grade B, Grade C

Novelty: Grade A, Grade B, Grade

В

Creativity or Innovation: Grade A,

Grade B, Grade B

Scientific Significance: Grade B,

Grade B, Grade C

P-Reviewer: He L; Li R; Pappachan

JM; Zhang L

Received: January 2, 2025 Revised: April 22, 2025 Accepted: June 13, 2025 Published online: July 15, 2025 Processing time: 195 Days and 4.8

Hours



**Lei Gao**, **Jiang-Ning Wang**, Department of Orthopedics Surgery, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing 100038, China

**Zi-Xuan Liu**, Department of Clinical Medicine, Capital Medical University, Beijing 100038, China

Co-first authors: Lei Gao and Zi-Xuan Liu.

**Corresponding author:** Jiang-Ning Wang, MD, Chief Physician, Department of Orthopedics Surgery, Beijing Shijitan Hospital Affiliated to Capital Medical University, No. 10 Tieyi Road, Yangfangdian, Haidian District, Beijing 100038, China. wangjn@bjsjth.cn

# **Abstract**

#### **BACKGROUND**

Diabetic foot ulcer (DFU) is a serious and destructive complication of diabetes, which has a high amputation rate and carries a huge social burden. Early detection of risk factors and intervention are essential to reduce amputation rates. With the development of artificial intelligence technology, efficient interpretable predictive models can be generated in clinical practice to improve DFU care.

#### AIN

To develop and validate an interpretable model for predicting amputation risk in DFU patients.

#### **METHODS**

This retrospective study collected basic data from 599 patients with DFU in Beijing Shijitan Hospital between January 2015 and June 2024. The data set was randomly divided into a training set and test set with fivefold cross-validation. Three binary variable models were built with the eXtreme Gradient Boosting (XGBoost) algorithm to input risk factors that predict amputation probability. The model performance was optimized by adjusting the super parameters. The predictive performance of the three models was expressed by sensitivity, specificity, positive predictive value, negative predictive value and area under the curve (AUC). Visualization of the prediction results was realized through SHapley Additive exPlanation (SHAP).

#### **RESULTS**

A total of 157 (26.2%) patients underwent minor amputation during hospitalization and 50 (8.3%) had major amputation. All three XGBoost models demonstrated good discriminative ability, with AUC values > 0.7. The model for predicting major amputation achieved the highest performance [AUC = 0.977, 95% confidence interval (CI): 0.956-0.998], followed by the minor amputation model (AUC = 0.800, 95%CI: 0.762-0.838) and the nonamputation model (AUC = 0.772, 95%CI: 0.730-0.814). Feature importance ranking of the three models revealed the risk factors for minor and major amputation. Wagner grade 4/5, osteomyelitis, and high C-reactive protein were all considered important predictive variables.

#### **CONCLUSION**

XGBoost effectively predicts diabetic foot amputation risk and provides interpretable insights to support personalized treatment decisions.

Key Words: Diabetic foot ulcer; Amputation risk stratification; Clinical risk prediction; eXtreme Gradient Boosting; SHapley Additive exPlanation; Machine learning

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study developed and validated an eXtreme Gradient Boosting-based predictive model for stratifying amputation risk in patients with diabetic foot ulcers. By integrating 29 clinical variables and applying SHapley Additive exPlanation for interpretability, the model achieved high predictive accuracy, especially for major amputations (area under the curve = 0.977). Key predictors included Wagner grade, albumin, infection markers, and vascular intervention. The model allows for the early identification of high-risk patients and supports individualized treatment decisions, offering a clinically interpretable tool for improving diabetic foot management.

Citation: Gao L, Liu ZX, Wang JN. Predictive model and risk analysis for outcomes in diabetic foot ulcer using eXtreme Gradient Boosting algorithm and SHapley Additive exPlanation. World J Diabetes 2025; 16(7): 104789

**URL:** https://www.wjgnet.com/1948-9358/full/v16/i7/104789.htm

**DOI:** https://dx.doi.org/10.4239/wjd.v16.i7.104789

#### INTRODUCTION

Diabetic foot ulcer (DFU) is one of the most serious complications of diabetes, and it is primarily caused by diabetic peripheral neuropathy and peripheral arterial disease. It is also the leading cause of nontraumatic lower extremity amputation (LEA)[1,2]. Amputation has a significant impact on the prognosis of DFU patients, reducing their quality of life and increasing their mortality rate [3-5]. Amputation increases treatment costs fivefold, thereby increasing the burden on the national healthcare system[6]. DFU amputations can be divided into minor amputations below the ankle joint and major amputations above the ankle joint. A meta□analysis from China showed that the overall LEA rate in DFU patients was 31%[7]. Major amputation leads to more severe physical disability and poor socio-economic function than minor amputation. Over one million diabetes patients lose part of their legs every year due to improper management of DFU[8]. Therefore, early detection of amputation risk in DFU can potentially benefit many patients[9,10].

An effective classification system that provides early indicators of disease severity could assist clinical decision-making [10-12]. Oyibo et al[13] showed that the Wagner and Texas systems are effective for predicting DFU outcomes, with higher grades of DFU in these classifications correlating with an increased amputation risk. However, these classification methods are limited in describing wounds as they do not account for factors such as infection severity, wound size, and vascular pathology. Hicks et al[14] suggested that the WIFI (W: wound; I: Ischemia; FI: Foot infection) system might be relevant for limb preservation and wound healing, as it can predict 1-year healing outcomes in DFU patients. In contrast, the prediction model based on statistical methods integrates more factors to estimate the probability of amputation risk early and offer more direct guidance for clinicians.

In recent decades, machine learning has evolved from a primitive technology to the cornerstone of medical data analysis[15]. Previous predictive modeling methods, such as artificial neural networks (ANNs) and support vector machines (SVMs), are commonly used for single linear relationship analysis and feature extraction [16,17]. eXtreme Gradient Boosting (XGBoost) is an integrated tree lift algorithm that can flexibly process missing data and combine weak predictive models to screen significant features of accurate models[18]. However, most people consider this algorithm to be indescribable. The trust of patients and clinicians in model predictions has been limited [19]. SHapley Additive exPlanations (SHAP) can be used to analyze feature importance, where all features are treated as contributors. The influence of each predictor on the target variable can be directly expressed, whether positive or negative [20,21]. SHAP can be utilized to interpret and analyze model output results and to improve the model's efficiency. Liu et al[22] developed an XGBoostbased mortality prediction model for intensive care unit patients with acute kidney injury, demonstrating its potential for early risk stratification and timely intervention in critically ill individuals. Hou et al [23] and Hu et al [24] both applied XGBoost to mortality prediction in sepsis patients. Hou et al achieved an area under the curve (AUC) of 0.857 for 30-day mortality, outperforming logistic regression, while Hu et al reported an AUC of 0.884 for in-hospital mortality, further enhancing model interpretability with SHAP values.

Here, we attempt to study a hierarchical predictive model that fully incorporated risk factors for diabetic foot amputation and analyzed the relationship between these factors. We hope that early intervention of patients with high risk factors can reduce amputation rate and improve the long-term prognosis.

#### MATERIALS AND METHODS

#### Study design and participants

This study was performed in accordance with the International Conference on Harmonization of Good Clinical Practice Guidelines and the Declaration of Helsinki and approved by the Ethical Review Committee of Beijing Shijitan Hospital, Capital Medical University [Ethical approval number (IIT2025-049-001)]. This study was a retrospective analysis of anonymized clinical data. Ethical approval was obtained from the Institutional Review Board, and the requirement for informed consent was waived.

Patients with DFU who were admitted to the Beijing Shijitan Hospital Affiliated to Capital Medical University between January 2015 and June 2024 were randomly selected and assembled into groups, as outlined in Figure 1. Patients who died during hospitalization, underwent amputation prior to transfer to Beijing Shijitan Hospital, those who sought treatment at other medical institutions during hospitalization, and those with incomplete information where missing values were identified in the dataset, were excluded. Participants' clinical information was extracted from electronic health records (EHRs).

Based on clinical practice, international guidelines from the International Working Group on the Diabetic Foot, and a comprehensive literature review [25-27], candidate variables were screened for inclusion. Further selection was conducted according to the availability and completeness of data within the EHRs, ensuring data integrity and no missing values to support robust statistical analysis and model performance. This process yielded a final set of 29 variables encompassing patient demographics, medical history, clinical and laboratory indicators, Wagner ulcer classification, nutritional status, wound characteristics, ischemia-related factors, and clinical outcomes (e.g., amputation status).

Subjects were divided into three groups based on treatment outcomes: (1) Non-amputation group (n = 392); (2) Minor amputation group (n = 157); and (3) Major amputation group (n = 50).

#### Statistical analysis

Descriptive statistical analysis of the data was performed for each of the three groups. The Shapiro-Wilk test was used to assess the normality of continuous variables. The characteristics of the normal distribution are represented as mean ± SD, whereas those with non-normal distribution are denoted by median with interquartile range. To evaluate statistical significance between two groups, the t test was applied for normally distributed features, and the Mann-Whitney U test for abnormally distributed features. Categorical variables are expressed as counts (n) and percentages (%). The intergroup difference variables were tested by Pearson's  $\chi^2$  test. P < 0.05 was considered statistically significant. All of the above calculations were performed using SPSS Version 27.0.

#### Model construction

Variable selection for model training: No dimensionality reduction or manual prescreening was applied before model training. Instead, a data-driven approach was adopted by inputting all 29 clinically relevant variables, selected based on guidelines and literature, directly into the model. The XGBoost algorithm automatically assessed the contribution of each variable during training through its built-in feature selection mechanism based on split gain and frequency.

Class weighting for the imbalanced dataset: To address the potential class imbalance between different amputation groups (non-amputation, minor amputation, and major amputation), the scale\_pos\_weight parameter was applied in the XGBoost algorithm, referencing the methodological approach of Méndez Barrera et al [28], who applied machine learning techniques to address data imbalance in predictive modeling. This parameter adjusts the weight of the positive class to counterbalance the disparity in sample sizes across the classes.

Specifically, for each binary classification model, we calculated the scale\_pos\_weight as the ratio of number of negative samples to the number of positive samples, as follows: scale\_pos\_weight = Number of negative samples/number of

This adjustment ensured that the model gave more emphasis to the minority class (major amputation), thereby improving the predictive accuracy for rare outcomes. integration of the scale\_pos\_weight parameter into the XGBoost model helped to mitigate the effect of class imbalance and enhance the model's ability to predict the minority class with greater accuracy.

Data preprocessing: The dataset was confirmed to not contain any missing values during data preprocessing; therefore, no imputation or data cleaning for incomplete entries was necessary.

Data preprocessing included continuous variable discretization and dummy variable processing. The quantile method for discretizing continuous variables was chosen over equal-width binning or k-means clustering primarily because it effectively handles skewed data distributions. Unlike equal-width binning, which divides the data range into equal-sized intervals, the quantile method ensures that each bin contains an equal number of samples, preventing bins from having




Figure 1 Multi-classification grouping flow chart of amputation prediction for diabetic foot ulcer patients.

too few data points, especially when outliers are present. Compared to k-means clustering, the quantile method is simpler, more stable, and does not require complex initialization or iterative optimization. Additionally, it better preserves the distributional characteristics of the data, improving the predictive accuracy and robustness of the model. The discretization process replaced continuous variables with ordered classification variables using the quantile method, while dummy variable processing was applied to convert categorical variables into a format suitable for model handling [29].

**Dataset partitioning:** After the above steps, the training set and test set were converted to matrix format. The dataset was randomly divided into training (80%) and calibration datasets (20%). The training set was constructed using fivefold cross-validation to ensure that the model learned enough features and patterns. The validation set evaluated the generalization ability of the model after model training.

**Add validation set and early stopping strategy:** To avoid overfitting, an early stop strategy was built into the training process. When performance was no longer improved on the verification set, the training was stopped.

**Model parameter setting:** Parameters of the model were defined in the study and model performance was optimized through hyperparameter optimization. A grid search strategy combined with fivefold cross-validation was applied to optimize the XGBoost model hyperparameters. By systematically evaluating predefined combinations of parameter values, the optimal configuration for model performance was identified. Key parameters tuned during this process included the maximum tree depth (max\_depth), learning rate (eta), subsample ratio (subsample), column sampling ratio (colsample\_bytree), and min\_child\_weight. Model performance was assessed using logarithmic loss (logloss) and the AUC, and the best-performing parameter set was selected for final model training[20].

Parameters: Booster: Specifies the type of tree model used; gbtree was selected, which is the gradient boosting tree. Objective: Defines the optimization objective of the model; binary was used here. Logistic, which is for binary classification and suitable for classification problems. ETA: Learning rate, which controls the complexity of the tree in each iteration. A smaller value can increase model stability. Max\_depth: Maximum depth of the tree, which controls model complexity and prevents overfitting. Eval\_metric: The metric used to evaluate model performance; logloss (logarithmic loss) was used here. Min\_child\_weight: A hyperparameter in XGBoost that controls the minimum sum of instance weights (Hessian) required in a child node. Subsample: A hyperparameter in XGBoost that controls the fraction of training data randomly sampled for each boosting iteration. It acts as a form of regularization by introducing randomness into the model training process, which can help reduce overfitting and improve generalization. Colsample\_bytree: A hyperparameter in XGBoost that specifies the fraction of features (columns) randomly sampled when constructing each decision tree. It introduces feature-level randomness during training, which serves as a regularization technique to reduce overfitting and improve model generalization-particularly useful in datasets with many correlated variables.

Model prediction: The characteristic variables passed through multiple decision trees in turn. Each tree classified the sample to a leaf node and output the predicted value of that sample. The predicted values of all trees were added to form the overall prediction of the model. The output result was the probability of amputation, which transformed accumulation to the second classification result of an amputation through logical regression.

#### Model evaluation

Five model evaluation indicators were used: AUC, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). These indicators helped to evaluate the model when predicting different amputation types. Overall performance was represented by weighted average performance across categories. Category weights represent the proportion of each category.

The standard formulas for calculating sensitivity, specificity, PPV and NPV are below. These metrics were derived from the confusion matrix using the following definitions [30]: Sensitivity (Recall) = TP/(TP + FN); Specificity = TN/(TN + FP); PPV = TP/(TP + FP); NPV = TN/(TN + FN); where, TP = true positives; TN = true negatives; FP = false positives;

The default threshold of 0.5 was used for binary classification, where predicted probabilities ≥ 0.5 were classified as positive. This threshold was used consistently across models to allow for standard comparison of classification performance[31].

# Calibration assessment

To evaluate the calibration performance of the three amputation risk prediction models (non-amputation, minor amputation, and major amputation), a comprehensive calibration analysis was conducted that included: (1) Calibration curve plotting; (2) Hosmer-Lemeshow goodness-of-fit test; and (3) Brier score calculation[32].

For each model, calibration curves were constructed using bootstrapping (B = 1000 iterations) to visualize the agreement between predicted probabilities and observed event rates. The mean absolute error and mean squared error were calculated from the calibration curves to quantify deviation.

The Hosmer-Lemeshow test was used to assess fit between observed and expected probabilities. A nonsignificant Pvalue (> 0.05) indicated good calibration.

The Brier score, representing the mean squared difference between predicted probabilities and actual binary outcomes, was calculated for each model. Lower Brier scores indicated better calibration.

#### Feature importance ranking

As an efficient multithreaded model processing method, XGBoost has built-in feature importance analysis function to optimize model efficiency by removing irrelevant features that contribute little to the model [33]. Each observation within the dataset could be elucidated by a distinct set of SHAP values. Model construction, evaluation and feature importance ranking were performed using standard Python packages (Python 3.8.1).

## RESULTS

# Univariable analysis results

Between January 2015 and June 2024, there were 599 patients with DFUs, comprising 420 (70.1%) males and 179 (29.9%) females, aged 46-96 years. The demographic characteristics, disease profiles, and treatment modalities of all patients categorized by amputation status are presented in Table 1. Among these individuals, 157 (26.2%) underwent minor amputation during hospitalization, while 50 (8.3%) underwent major amputation.

Markers of inflammation [including white blood cells, C-reactive protein (CRP), and procalcitonin] and renal function indicators [creatinine and blood urea nitrogen (BUN)] dramatically increased. More severe foot ulcerations, as assessed by the Wagner scale and wound extent, as well as history of coronary heart disease and renal dysfunction were notably prevalent among amputees. Additionally, most patients received antibiotic treatment prior to admission, with an increase in the proportion of osteomyelitis cases. In contrast with patients who underwent minor amputation, those with major amputation had elevated markers of myocardial injury (myoglobin), reduced albumin and triglyceride levels, significantly higher frequencies of Wagner grades 4/5, and diminished rates of interventional therapy.

T 11 4	<b>B</b>			4 4 1			(OD)
Lable 1	Descrin	tive stat	tistics and	test anal	iveie nt	' variahles	. mean (SD)

Corneir   Formale   129 (23.9)   36 (22.9)   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   14 (26.9)   0.067   15 (20.9)   0.068   0.068   0.0	Variables	Non-amputation (n = 392)	Minor amputation (n = 157)	Major amputation $(n = 50)$	P value
Pennale	Demographic data				
Male         263 (67.1)         121 (77.1)         36 (72.0)         37.0	Gender				
Age: year         68.29 (9.99)         70.60 (9.20)         68.88 (0.25)         0.30 (2.20)           Diabetes duration         17.13 (0.43)         18.66 (0.00)         18.89 (8.99)         0.138           Modical history         Februarision           Experiencial         152 (08.8)         7 (45.2)         15 (00.0)         0.128           Yes         240 (61.2)         86 (54.8)         36 (70.0)         0.44           Yes         240 (61.2)         118 (75.2)         36 (72.0)         0.44           Yes         279 (71.2)         118 (75.2)         36 (72.0)         0.44           Yes         131 (28.8)         30 (24.8)         142.00         12.00           Tyes         145 (87.0)         41 (26.1)         23 (60.0)         0.012           Yes         247 (63.0)         116 (73.9)         27 (64.0)         0.012           Yes         354 (90.3)         145 (92.4)         44 (80.0)         0.604           Yes         354 (90.3)         145 (92.4)         44 (80.0)         0.604           Yes         20 (60.4)         149 (94.9)         48 (96.0)         0.81           Yes         20 (56.0         8 (51)         2 (80.0)         0.72           Ye	Female	129 (32.9)	36 (22.9)	14 (28.0)	0.067
Diabets duration (years)  Diabets duration (17.13 (9.43) 18.66 (9.00) 18.89 (8.99) 0.138 (7.14 (1.14	Male	263 (67.1)	121 (77.1)	36 (72.0)	
Desires duration   17.10 (4.5)   18.60 (9.01)   18.90 (8.90)   0.128   18.50 (17.50	Age: year	68.28 (9.99)	67.06 (9.20)	68.88 (9.25)	0.336
September   Sept	Diabetes duration (years)				
No 152 (38.8) 71 (45.2) 15 (30.0) 0.128 (30.0) 15 (30.0) 0.128 (30.0) 15 (30.0) 0.128 (30.0) 15	Diabetes duration	17.13 (9.43)	18.66 (9.00)	18.89 (8.99)	0.138
No         152 (38.8)         71 (45.2)         15 (30.0)         0.128           Yes         240 (61.2)         86 (54.8)         35 (70.0)         1           Hyperdipidemia           No         279 (71.2)         118 (75.2)         36 (72.0)         0.640           Coronary heart disease           No         145 (87.0)         41 (26.1)         23 (46.0)         0.012           Yes         145 (87.0)         41 (26.1)         23 (46.0)         0.012           Yes         145 (87.0)         41 (26.1)         23 (46.0)         0.012           Yes         145 (97.0)         41 (26.1)         23 (40.0)         0.012           Heart attack           No         354 (90.3)         145 (92.4)         44 (88.0)         0.604           Yes         36 (9.7)         12 (7.6)         46 (20.0)         0.881           Yes         2 (26.6)         8 (5.1)         2 (40.0)         0.343           Yes         2 (26.6)         8 (5.1)         2 (40.0)         0.343           Yes         2 (27.4)         107 (68.2)         31 (62.0)         0.343           Yes         12 (28.6)         109 (88.5)         44 (88.0)         0.705	Medical history				
Yes         240 (61.2)         86 (54.8)         35 (70.0)         Hyperlipidemia           No         279 (71.2)         118 (75.2)         36 (72.0)         0.640           Yes         113 (28.8)         39 (24.8)         14 (28.0)         14 (28.0)           Coronary heart disease           No         145 (37.0)         41 (26.1)         23 (46.0)         0.012           Yes         247 (63.0)         116 (73.9)         27 (54.0)         14 Heart attack           No         354 (90.3)         145 (82.4)         4 (88.0)         0.604           Yes         36 (97.)         12 (7.6)         612.0)         0.604           Yes         36 (97.)         12 (7.6)         612.0         0.604           Yes         25 (5.6)         8 (5.1)         2.0         0.881           Yes         22 (5.6)         8 (5.1)         2.0         0.0         0.881           Yes         12 (12.8)         50 (3.8)         19 (38.0)         0.343         0.0         0.0         0.2         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0         0.0	Hypertension				
Hyperlipidemia         No         279 (71.2)         118 (75.2)         36 (72.0)         0.640           Yes         113 (28.8)         39 (24.8)         14 (28.0)         4           Coronary heart disease           No         145 (37.0)         41 (26.1)         23 (46.0)         0.012           Yes         247 (83.0)         116 (73.9)         27 (54.0)         4           Heart attack           No         354 (90.3)         145 (92.4)         44 (88.0)         .664           Yes         38 (97.0)         12 (7.6)         6 (12.0)            No         354 (90.3)         149 (94.9)         48 (96.0)             Yes         22 (5.6)         8 (5.1)         2 (4.0) <td>No</td> <td>152 (38.8)</td> <td>71 (45.2)</td> <td>15 (30.0)</td> <td>0.128</td>	No	152 (38.8)	71 (45.2)	15 (30.0)	0.128
No 279 (71.2) 118 (75.2) 36 (72.0) 0.640 Yes 113 (28.8) 39 (24.8) 14 (28.0)  Coronary heart disease  No 145 (37.0) 41 (26.1) 23 (46.0) 0.012 Yes 247 (63.0) 116 (73.9) 27 (54.0)  Heart attack  No 354 (90.3) 145 (92.4) 44 (88.0) 0.664 Yes 38 (9.7) 12 (7.6) 612.0)  Atrial fibrillation  No 370 (94.4) 149 (94.9) 48 (96.0) 0.881 Yes 22 (36.0) 8 (3.1) 24 (90.0)  Ves 22 (36.0) 15 (18.0) 17 (98.2) 31 (62.0) 0.881  Corebrovascular disease  No 280 (71.4) 107 (68.2) 31 (62.0) 0.343 Yes 112 (28.6) 50 (18.8) 19 (88.0) 0.001  Corebrovascular disease  No 355 (90.6) 139 (88.5) 44 (88.0) 0.705 Yes 37 (94.4) 18 (11.5) 61 (12.0)  No 38 (9.7) 35 (22.3) 12 (24.5) 50 (10.1)  Renal insufficiency  No 38 (9.7) 35 (22.3) 12 (24.5) 50 (10.1)  Yes 34 (30.3) 122 (77.7) 37 (75.5)  Clinical and laboratory data  WBC (10"/1) 415 (51.90) 73.31 (77.84) 99.43 (88.93) 6.001  PCI (10g/mL) 625 (68.78) 6.44 (1.01) 6.67 (1.19) 6.001  HBAIC (35) 8.43 (68.71) 6.47 (10.329) 10.44 (34.59) 6.720  Corell (18.4) 6.64 (68.71) 4.70 (13.29) 10.44 (34.59) 6.720  Corell (18.4) 6.64 (68.71) 6.64 (11.7) 2.08 (14.8) 6.720  Corell (18.4) 6.75 (19.4)	Yes	240 (61.2)	86 (54.8)	35 (70.0)	
Yes         13 (28.8)         39 (24.8)         14 (26.0)         Image: Coronary heart disease           No         145 (37.0)         41 (26.1)         23 (46.0)         0.012           Yes         247 (63.0)         116 (73.9)         27 (54.0)         Image: Coronary heart disease           Heart attack         Image: Coronary heart disease         Image: Coronary heart disease         44 (88.0)         0.604           No         354 (90.3)         145 (92.4)         44 (88.0)         0.604           Yes         38 (97.1)         149 (94.9)         48 (96.0)         0.881           No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         2 (2.6)         8 (3.1)         2 (4.0)         1.00           Cerebrovascular disease         Vere         112 (28.6)         50 (31.8)         19 (38.0)         3.33           Chronic lung disease         Vere         37 (94.0)         139 (88.5)         44 (88.0)         0.705           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (94.0)         150 (15.0)         0.705           No         36 (90.0)         15 (15.0)         37 (75.5)           Vers         3	Hyperlipidemia				
Coronary heart disease         No         145 (37.0)         41 (26.1)         23 (46.0)         0.012           Yes         247 (63.0)         116 (73.9)         27 (54.0)         145 (24.0)         145 (24.0)         145 (24.0)         145 (24.0)         145 (24.0)         145 (22.4)         44 (88.0)         0.604         145 (22.4)         44 (88.0)         0.604         145 (22.4)         44 (88.0)         0.604         145 (22.4)         44 (88.0)         0.604         145 (22.4)         44 (88.0)         0.604         145 (22.4)         44 (88.0)         0.604         145 (22.4)         145 (22.4)         48 (96.0)         0.881         145 (22.4)         145 (22.4)         48 (96.0)         0.881         145 (22.4)	No	279 (71.2)	118 (75.2)	36 (72.0)	0.640
No         145 (37.0)         41 (26.1)         23 (46.0)         0.012           Yes         247 (63.0)         116 (73.9)         27 (54.0)         1           Heart attack           No         354 (90.3)         145 (92.4)         44 (88.0)         0.604           Yes         38 (97)         12 (7.6)         (12.0)         1           Attrial fibrillation           No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         22 (5.6)         8 (5.1)         2 (4.0)         2           Cerebrovascular disease           No         280 (71.4)         107 (68.2)         31 (62.0)         0.343           Templational disease           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Templational disease           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Templational disease         37 (9.4)         18 (11.5)         20 (20.0)         20 (20.0)           Read insufficiency         No         35 (90.6)         35 (22.3)         12 (24.5)	Yes	113 (28.8)	39 (24.8)	14 (28.0)	
Yes         247 (63.0)         116 (73.9)         27 (54.0)         Heart attack           No         354 (90.3)         145 (92.4)         44 (88.0)         0.604           Yes         38 (97)         12 (7.6)         6(12.0)           Atrial fibrillation           No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         22 (5.6)         8 (5.1)         2 (4.0)         200           Cerebrovascular disease           No         280 (71.4)         107 (68.2)         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)         0.343           Chronic lung disease           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (9.4)         18 (11.5)         6 (12.0)         0.705           Renal insufficiency           No         38 (9.7)         35 (22.3)         12 (24.5)         <0.001	Coronary heart disease				
Heart attack         No         354 (90.3)         145 (92.4)         44 (88.0)         0.604           Yes         38 (9.7)         12 (7.6)         6 (12.0)           Atrial fibrillation         No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         22 (5.6)         8 (5.1)         2 (4.0)         851           Cerebrovascular disease         No         280 (71.4)         107 (68.2)         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)         0.705           Chronic lung disease         No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (9.4)         18 (1.5)         6 (12.0)           Renal insufficiency         No         38 (9.7)         35 (22.3)         12 (24.5)         <0.001	No	145 (37.0)	41 (26.1)	23 (46.0)	0.012
No         354 (90.3)         145 (92.4)         44 (88.0)         6.04           Yes         38 (9.7)         12 (7.6)         6 (12.0)           Atrial fibrillation           No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         22 (5.6)         8 (5.1)         2 (4.0)           Cerebrovascular disease           No         280 (71.4)         107 (68.2)         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)         19 (38.0)           Chronic lung disease           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (9.4)         18 (11.5)         6 (12.0)         705           Renal insufficiency         18 (11.5)         4 (88.0)         0.705         0.705           Renal insufficiency         2         35 (22.3)         12 (24.5)         0.001         0.001           Yes         34 (90.3)         122 (77.7)         37 (75.5)         1.000         0.001         0.001         0.001         0.001         0.001         0.001         0.001         0.001         0.001         0.001         0.001	Yes	247 (63.0)	116 (73.9)	27 (54.0)	
Yes         38 (9.7)         12 (7.6)         6 (12.0)           Atrial fibrillation         No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         22 (5.6)         8 (5.1)         2 (4.0)           Cerebrovascular disease         No         280 (71.4)         107 (68.2)         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)         70           Chronic lung disease         No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (9.4)         18 (11.5)         6 (12.0)         70           Renal insufficiency         No         38 (9.7)         35 (22.3)         12 (24.5)         <0.001           Yes         36 (90.3)         122 (77.7)         37 (75.5)            Clinical and laboratory data           WBC (10°/L)         8.38 (4.53)         9.88 (5.00)         11.45 (6.34)         <0.001           CRP (mg/L)         41.51 (51.90)         73.31 (77.84)         99.43 (88.93)         <0.001           PCT (ng/mL)         0.25 (0.63)         0.44 (1.01)         0.67 (1.19)         <0.001           HbA1c (%)         8.	Heart attack				
Atrial fibrillation         No         370 (94.4)         149 (94.9)         48 (96.0)         0.881           Yes         22 (5.6)         8 (5.1)         2 (4.0)           Cerebrovascular disease         Veres         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)           Chronic lung disease         Veres         37 (9.4)         139 (88.5)         44 (88.0)         0.705           Yes         37 (9.4)         18 (11.5)         6 (12.0)         Veres         0.001           Renal insufficiency         Veres         354 (90.3)         122 (77.7)         37 (75.5)         0.001           Ves         354 (90.3)         122 (77.7)         37 (75.5)         0.001         0.001           Clinical and laboratory data         Veres         8.38 (4.53)         9.88 (5.00)         11.45 (6.34)         < 0.001	No	354 (90.3)	145 (92.4)	44 (88.0)	0.604
No       370 (94.4)       149 (94.9)       48 (96.0)       0.881         Yes       22 (5.6)       8 (5.1)       2 (4.0)         Cerebrovascular disease         No       280 (71.4)       107 (68.2)       31 (62.0)       0.343         Yes       112 (28.6)       50 (31.8)       19 (38.0)       19 (38.0)         Chronic lung disease         No       355 (90.6)       139 (88.5)       44 (88.0)       0.705         Yes       37 (9.4)       18 (11.5)       6 (12.0)       70         Renal insufficiency         No       38 (9.7)       35 (22.3)       12 (24.5)       <0.001         Yes       354 (90.3)       122 (77.7)       37 (75.5)         Clinical and laboratory data         WBC (10°/L)       8.38 (4.53)       9.88 (5.00)       11.45 (6.34)       <0.001         CRP (mg/L)       41.51 (51.90)       73.31 (77.84)       99.43 (88.93)       <0.001         PCT (ng/mL)       0.25 (0.63)       0.44 (1.01)       0.67 (1.19)       <0.001         HbA1c (%)       8.07 (250)       8.43 (2.02)       8.38 (1.86)       0.218         Mb (ng/mL)       51.27 (68.78)       52.15 (77.34)       96.16 (123.04)	Yes	38 (9.7)	12 (7.6)	6 (12.0)	
Yes         22 (5.6)         8 (5.1)         2 (4.0)           Cerebrovascular disease           No         280 (7.14)         107 (68.2)         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)           Chronic lung disease           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (94)         18 (11.5)         6 (12.0)           Renal insufficiency           No         38 (9.7)         35 (22.3)         12 (24.5)         <0.001	Atrial fibrillation				
Cerebrovascular disease           No         280 (71.4)         107 (68.2)         31 (62.0)         0.343           Yes         112 (28.6)         50 (31.8)         19 (38.0)           Chronic lung disease           No         355 (90.6)         139 (88.5)         44 (88.0)         0.705           Yes         37 (9.4)         18 (11.5)         6 (12.0)           Renal insufficiency           No         38 (9.7)         35 (22.3)         12 (24.5)         < 0.001	No	370 (94.4)	149 (94.9)	48 (96.0)	0.881
No 280 (71.4) 107 (68.2) 31 (62.0) 0.343 Yes 112 (28.6) 50 (31.8) 19 (38.0)  Chronic lung disease  No 355 (90.6) 139 (88.5) 44 (88.0) 0.705 Yes 37 (9.4) 18 (11.5) 6 (12.0)  Renal insufficiency  No 38 (9.7) 35 (22.3) 12 (24.5) <0.001 Yes 354 (90.3) 122 (77.7) 37 (75.5)  Clinical and laboratory data  WBC (10 <sup>9</sup> /L) 8.38 (4.53) 9.88 (5.00) 11.45 (6.34) <0.001 CRP (mg/L) 41.51 (51.90) 73.31 (77.84) 99.43 (88.93) <0.001 PCT (ng/mL) 0.25 (0.63) 0.44 (1.01) 0.67 (1.19) <0.001 HbA1c (%) 8.07 (2.50) 8.43 (2.02) 8.38 (1.86) 0.218 Mb (ng/mL) 51.27 (68.78) 52.15 (77.34) 96.16 (123.04) <0.001 Tn (ng/mL) 8.64 (68.71) 4.70 (13.29) 10.44 (34.59) 0.720 CK-MB (µg/mL) 1.89 (1.97) 1.63 (1.17) 2.08 (1.48) 0.180	Yes	22 (5.6)	8 (5.1)	2 (4.0)	
Yes       112 (28.6)       50 (31.8)       19 (38.0)         Chronic lung disease         No       355 (90.6)       139 (88.5)       44 (88.0)       0.705         Yes       37 (9.4)       18 (11.5)       6 (12.0)         Renal insufficiency         No       38 (9.7)       35 (22.3)       12 (24.5)       < 0.001	Cerebrovascular disease				
Chronic lung disease         No       355 (90.6)       139 (88.5)       44 (88.0)       0.705         Yes       37 (9.4)       18 (11.5)       6 (12.0)         Renal insufficiency         No       38 (9.7)       35 (22.3)       12 (24.5)       < 0.001	No	280 (71.4)	107 (68.2)	31 (62.0)	0.343
No 355 (90.6) 139 (88.5) 44 (88.0) 0.705 Yes 37 (9.4) 18 (11.5) 6 (12.0)  Renal insufficiency  No 38 (9.7) 35 (22.3) 12 (24.5) <0.001 Yes 354 (90.3) 122 (77.7) 37 (75.5)  Clinical and laboratory data  WBC (10 <sup>9</sup> /L) 8.38 (4.53) 9.88 (5.00) 11.45 (6.34) <0.001 CRP (mg/L) 41.51 (51.90) 73.31 (77.84) 99.43 (88.93) <0.001 PCT (ng/mL) 0.25 (0.63) 0.44 (1.01) 0.67 (1.19) <0.001 HbΔ1c (%) 8.07 (2.50) 8.43 (2.02) 8.38 (1.86) 0.218 Mb (ng/mL) 51.27 (68.78) 52.15 (77.34) 96.16 (123.04) <0.001 Tn (ng/mL) 8.64 (68.71) 4.70 (13.29) 10.44 (34.59) 0.720 CK-MB (μg/mL) 1.89 (1.97) 1.63 (1.17) 2.08 (1.48) 0.180	Yes	112 (28.6)	50 (31.8)	19 (38.0)	
Yes       37 (9.4)       18 (11.5)       6 (12.0)         Renal insufficiency       Companies       Companies       Companies         No       38 (9.7)       35 (22.3)       12 (24.5)       < 0.001         Yes       354 (90.3)       122 (77.7)       37 (75.5)         Clinical and laboratory data         WBC (109/L)       8.38 (4.53)       9.88 (5.00)       11.45 (6.34)       < 0.001         CRP (mg/L)       41.51 (51.90)       73.31 (77.84)       99.43 (88.93)       < 0.001         PCT (ng/mL)       0.25 (0.63)       0.44 (1.01)       0.67 (1.19)       < 0.001         HbA1c (%)       8.07 (2.50)       8.43 (2.02)       8.38 (1.86)       0.218         Mb (ng/mL)       51.27 (68.78)       52.15 (77.34)       96.16 (123.04)       < 0.001         Tn (ng/mL)       8.64 (68.71)       4.70 (13.29)       10.44 (34.59)       0.720         CK-MB (µg/mL)       1.89 (1.97)       1.63 (1.17)       2.08 (1.48)       0.180	Chronic lung disease				
Renal insufficiency         No       38 (9.7)       35 (22.3)       12 (24.5)       < 0.001         Yes       354 (90.3)       122 (77.7)       37 (75.5)         Clinical and laboratory data         WBC (109/L)       8.38 (4.53)       9.88 (5.00)       11.45 (6.34)       < 0.001         CRP (mg/L)       41.51 (51.90)       73.31 (77.84)       99.43 (88.93)       < 0.001         PCT (ng/mL)       0.25 (0.63)       0.44 (1.01)       0.67 (1.19)       < 0.001         HbA1c (%)       8.07 (2.50)       8.43 (2.02)       8.38 (1.86)       0.218         Mb (ng/mL)       51.27 (68.78)       52.15 (77.34)       96.16 (123.04)       < 0.001         Tn (ng/mL)       8.64 (68.71)       4.70 (13.29)       10.44 (34.59)       0.720         CK-MB (µg/mL)       1.89 (1.97)       1.63 (1.17)       2.08 (1.48)       0.180	No	355 (90.6)	139 (88.5)	44 (88.0)	0.705
No       38 (9.7)       35 (22.3)       12 (24.5)       < 0.001         Yes       354 (90.3)       122 (77.7)       37 (75.5)         Clinical and laboratory data         WBC (109/L)       8.38 (4.53)       9.88 (5.00)       11.45 (6.34)       < 0.001         CRP (mg/L)       41.51 (51.90)       73.31 (77.84)       99.43 (88.93)       < 0.001         PCT (ng/mL)       0.25 (0.63)       0.44 (1.01)       0.67 (1.19)       < 0.001         HbA1c (%)       8.07 (2.50)       8.43 (2.02)       8.38 (1.86)       0.218         Mb (ng/mL)       51.27 (68.78)       52.15 (77.34)       96.16 (123.04)       < 0.001         Tn (ng/mL)       8.64 (68.71)       4.70 (13.29)       10.44 (34.59)       0.720         CK-MB (µg/mL)       1.89 (1.97)       1.63 (1.17)       2.08 (1.48)       0.180	Yes	37 (9.4)	18 (11.5)	6 (12.0)	
Yes       354 (90.3)       122 (77.7)       37 (75.5)         Clinical and laboratory data         WBC (10°/L)       8.38 (4.53)       9.88 (5.00)       11.45 (6.34)       < 0.001	Renal insufficiency				
Clinical and laboratory data  WBC (10 <sup>9</sup> /L) 8.38 (4.53) 9.88 (5.00) 11.45 (6.34) < 0.001  CRP (mg/L) 41.51 (51.90) 73.31 (77.84) 99.43 (88.93) < 0.001  PCT (ng/mL) 0.25 (0.63) 0.44 (1.01) 0.67 (1.19) < 0.001  HbA1c (%) 8.07 (2.50) 8.43 (2.02) 8.38 (1.86) 0.218  Mb (ng/mL) 51.27 (68.78) 52.15 (77.34) 96.16 (123.04) < 0.001  Tn (ng/mL) 8.64 (68.71) 4.70 (13.29) 10.44 (34.59) 0.720  CK-MB (μg/mL) 1.89 (1.97) 1.63 (1.17) 2.08 (1.48) 0.180	No	38 (9.7)	35 (22.3)	12 (24.5)	< 0.001
WBC (109/L)       8.38 (4.53)       9.88 (5.00)       11.45 (6.34)       < 0.001	Yes	354 (90.3)	122 (77.7)	37 (75.5)	
CRP (mg/L)       41.51 (51.90)       73.31 (77.84)       99.43 (88.93)       < 0.001	Clinical and laboratory data				
PCT (ng/mL)       0.25 (0.63)       0.44 (1.01)       0.67 (1.19)       < 0.001	WBC (10 <sup>9</sup> /L)	8.38 (4.53)	9.88 (5.00)	11.45 (6.34)	< 0.001
HbA1c (%)       8.07 (2.50)       8.43 (2.02)       8.38 (1.86)       0.218         Mb (ng/mL)       51.27 (68.78)       52.15 (77.34)       96.16 (123.04)       < 0.001	CRP (mg/L)	41.51 (51.90)	73.31 (77.84)	99.43 (88.93)	< 0.001
Mb (ng/mL) 51.27 (68.78) 52.15 (77.34) 96.16 (123.04) < 0.001 Tn (ng/mL) 8.64 (68.71) 4.70 (13.29) 10.44 (34.59) 0.720 CK-MB (μg/mL) 1.89 (1.97) 1.63 (1.17) 2.08 (1.48) 0.180	PCT (ng/mL)	0.25 (0.63)	0.44 (1.01)	0.67 (1.19)	< 0.001
Tn (ng/mL) 8.64 (68.71) 4.70 (13.29) 10.44 (34.59) 0.720 CK-MB (μg/mL) 1.89 (1.97) 1.63 (1.17) 2.08 (1.48) 0.180	HbA1c (%)	8.07 (2.50)	8.43 (2.02)	8.38 (1.86)	0.218
CK-MB (μg/mL) 1.89 (1.97) 1.63 (1.17) 2.08 (1.48) 0.180	Mb (ng/mL)	51.27 (68.78)	52.15 (77.34)	96.16 (123.04)	< 0.001
	Tn (ng/mL)	8.64 (68.71)	4.70 (13.29)	10.44 (34.59)	0.720
Cr (µmol/L) 107.44 (138.29) 144.60 (191.22) 167.62 (202.93) 0.006	CK-MB (µg/mL)	1.89 (1.97)	1.63 (1.17)	2.08 (1.48)	0.180
	Cr (μmol/L)	107.44 (138.29)	144.60 (191.22)	167.62 (202.93)	0.006

BUN (mmol/L)	7.77 (4.50)	8.92 (5.40)	9.47 (7.07)	0.010
Albumin (g/L)	37.04 (5.74)	34.75 (5.48)	31.79 (5.21)	< 0.001
TC (mmol/L)	4.07 (1.21)	3.84 (1.15)	3.72 (1.93)	0.055
TG (mmol/L)	1.48 (0.89)	1.32 (0.68)	1.25 (0.73)	0.038
LDL-C (mmol/L)	2.37 (0.91)	2.38 (0.90)	2.12 (0.77)	0.166
Medication history				
Antibiotic use before hospitalization				
No	194 (49.5)	56 (35.7)	16 (32.0)	0.002
Yes	198 (50.5)	101 (64.3)	34 (68.0)	
Wound characteristics				
Wagner classification				
0-3	298 (76.0)	53 (33.8)	14 (28.0)	< 0.001
4/5	94 (24.0)	104 (66.2)	36 (72.0)	
Range				
≤ 5 cm	307 (78.3)	122 (77.7)	23 (46.0)	< 0.001
≥5 cm	85 (21.7)	35 (22.3)	27 (54.0)	
Osteomyelitis				
No	196 (50.0)	21 (13.4)	3 (6.0)	< 0.001
Yes	196 (50.0)	136 (86.6)	47 (94.0)	
Vascular intervention surgery				
No	310 (79.1)	87 (55.4)	33 (66.0)	< 0.001
Yes	82 (20.9)	70 (44.6)	17 (34.0)	

P values represent the results of intergroup trend analyses among the three groups, with P < 0.05 deemed significant. All continuous variables have been standardized, and binary variables with 0 representing no and 1 representing yes. WBC: White blood cell; CRP: C-reactive protein; PCT: Procalcitonin; HbA1c: Glycated hemoglobin; Mb: Myoglobin; Tn: Troponin; CK-MB: Creatine kinase isoenzyme; Cr: Creatinine; BUN: Blood urea nitrogen; TC: Total cholesterol; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol.

# Model manifestation

Parameter selection is crucial to the learning depth of the decision tree[34]. Therefore, we adjusted the parameters through fivefold cross-validation and grid search to identify the appropriate combination of parameters. The optimal parameters of the XGBoost model are shown in Table 2. To correct for class imbalance in each binary classification task, we applied the scale\_pos\_weight parameter in XGBoost, calculated as the ratio of negative to positive samples. The values were set as follows: 0.53 for the non-amputation model, 2.82 for the minor amputation model, and 10.98 for the major amputation model.

Patients were categorized into three distinct groups: Non-amputation, minor amputation, and major amputation. We conducted a binary classification analysis comparing the non-amputation group to the amputation groups, yielding a receiver operating characteristic (ROC) curve value of 0.772 for the model. Similarly, when we performed a binary classification analysis contrasting the non-amputation group with the minor amputation group, the ROC curve value for predicting minor amputations was 0.800. In our binary classification study comparing the non-amputation group with the major amputation group, we achieved an ROC curve value of 0.977 for predicting major amputations (Figure 2). Other assessment indexes of the model, such as sensitivity, specificity, NPV and PPV, are shown in Table 3.

Table 3 indicated that the multi-classification predictive model based on XGBoost had strong predictive ability: Minor amputation group AUC (0.800), sensitivity (78.1%), specificity (69.4%), NPV (61.0%) and PPV (83.8%); major amputation group AUC (0.977), sensitivity (98.7%), specificity (88.9%), NPV (88.9%) and PPV (98.7%). The confusion matrix identifies category blurring in machine learning and evaluated the accuracy of model predictions[29]. Figure 3 shows that the proportion of cases presenting false positives and false negatives was < 30%. Among them, the minor amputation model had the highest predictive accuracy, with only four prediction errors and an accuracy rate > 95%.

#### Model calibration metrics

Calibration curves: These calibration results suggest that all three models performed well. The major amputation model had the best performance, with the lowest error and excellent calibration, indicating strong predictive accuracy

Table 2 Parameter optimization results of eXtreme Gradient Boosting model				
Parameter	Default	Value		
Booster	Gbtree	Gbtree		
Objective	Reg: Linear	Binary: Logistic		
Eta	0.3	0.1		
Max_depth	6	6		
Eval_metric	Logloss	Logloss		
Colsample_bytree	1.0	0.5		
Subsample	1.0	0.5		
Min_child_weight	1.0	1.0		

Table 3 Various evaluation indicators of different models in the test set					
Evaluation_metrics	Non amputation (%)	Minor amputation (%)	Major amputation (%)		
Sensitivity	75.7	78.1	98.7		
Specificity	77.8	69.4	88.9		
NPV	66.0	61.0	88.9		
PPV	84.8	83.8	98.7		

NPV: Negative predictive value; PPV: Positive predictive value.




Figure 2 Receiver operating characteristic curves of the multi-category classification model. AUC: Area under the curve.

(Figure 4A). The minor amputation and non-amputation models were also well-calibrated, but with more errors, which suggests opportunities for refinement, particularly in the minor amputation model (Figure 4B and C).

**Hosmer-Lemeshow Goodness-of-Fit Test:** Non-amputation model:  $\chi^2$  = 5.9833, df = 8, P = 0.6491; minor amputation model:  $\chi^2 = 7.6315$ , df = 8, P = 0.4703; major amputation model:  $\chi^2 = 4.5485$ , df = 8, P = 0.8046. All models yielded P values > 0.05, indicating no significant deviation between predicted and observed outcomes and suggesting good overall model fitness.

Brier scores: Non-amputation model: 0.1643; minor amputation model: 0.1544; major amputation model: 0.0846. The lower Brier score for the major amputation model supports its superior predictive accuracy and calibration performance.




Figure 3 Confusion matrix of three classification models based on eXtreme Gradient Boosting. Different colors represent different frequencies, with the horizontal axis representing predicted values and the vertical axis representing actual values.

#### Interpretable explanatory model


We ranked the feature importance of the three models separately and obtained the following results (Figure 5). Wagner grading, CRP and procalcitonin (PCT) were important features among the three models. Osteomyelitis and higher BUN were also noteworthy risk factors in the minor and major amputation models. SHAP calculated the marginal contribution of features to the model output, helping to understand the impact of features on the predictive results of the model. We inputted the variables selected by ranking the importance of features into the SHAP library and constructed a Beeswarm graph (Figure 4A). For example, when explaining the minor amputation model, Wagner (grades 4/5), osteomyelitis, and vascular intervention therapy were ranked in the top three, all of which were positively correlated with outcomes. Similar explanations can also be used to analyze features that have a significant impact on decision-making in models of minor amputation and major amputation.


# DISCUSSION

This study presents an analysis of the clinical characteristics and amputation outcomes of DFU patients admitted to our hospital over the past decade. We used an XGBoost model to develop a multi-category classification framework encompassing 29 variables. Although our model was initially developed using 29 clinically relevant variables informed by international guidelines, existing literature, and EHR availability, we recognize that incorporating such a broad set may pose practical limitations in routine clinical environments. All 29 variables were retained during model training to avoid premature exclusion of potential predictors, ensuring that clinically meaningful yet less obvious features were not overlooked. To enhance real-world applicability, we utilized the embedded feature selection of XGBoost in conjunction with SHAP to quantify the predictive contribution of each variable. This analysis revealed that model performance was predominantly driven by a subset of 10-12 key variables, such as Wagner classification, serum albumin, PCT, vascular intervention status, and major comorbidities; all of which are commonly accessible in inpatient settings. These findings support the feasibility of developing a more streamlined model that retains predictive power and reduces clinical implementation burden.

The AUC of the XGBoost model for predicting non-amputation, minor amputation, and major amputation was 0.772, 0.800, and 0.977, respectively. These findings align with those of Wang et al[30], who evaluated various amputation prediction models and reported the accuracy for XGBoost (AUC: 0.726). However, their model was based solely on patients with Texas grade 3 DFUs, limiting its generalization to broader patient populations. In contrast, our study included a wider clinical spectrum, encompassing non-amputation, minor amputation, and major amputation groups, allowing for more nuanced stratification of amputation risk.

Traditional approaches to feature selection typically rely on expert judgment, univariate statistical methods, or logistic regression, often overlooking the potential for nonlinear interactions among variables. In contrast, our study integrated the embedded feature selection of XGBoost, which utilizes tree-based splitting gains, followed by SHAP values to rank and interpret the contribution of each feature. Rather than selecting features based solely on statistical significance, we used SHAP to identify those that consistently played a pivotal role in model predictions across different patient subgroups. This dual-step approach, combining the feature importance of XGBoost with SHAP validation, unearthed clinically relevant but previously underexplored predictors such as albumin, myoglobin, and vascular intervention, which were not highlighted in prior models. Traditional machine learning models[35], including logistic regression, SVMs and ANNs, often suffer from a lack of transparency and interpretability, which limits their applicability in clinical settings. In our study, we addressed this issue by constructing hierarchical binary classification models (e.g., nonamputation vs minor amputation; non-amputation vs major amputation), rather than a flat multiclass model, enabling more granular risk stratification aligned with clinical decision-making processes. The integration of XGBoost and SHAP enhanced both predictive accuracy (with AUC reaching 0.977 for major amputation) and model interpretability,







B = 1000 repetitions, boot Mean absolute error = 0.009 n = 422


Figure 4 Calibration curves for three classification models. A: Calibration curves for non-amputation model: B: Calibration curves for minor amputation model: C: Calibration curves for major amputation model. Apparent calibration (dotted line): This curve represents the raw, uncorrected calibration of the predicted probabilities of the model against the actual probabilities. The predictions of the model are plotted directly, and the apparent curve often deviates from the ideal (diagonal) line, indicating some level of bias in the model's prediction. Bias-corrected calibration (solid line): This curve corrects for the bias observed in the apparent calibration curve. It adjusts the predictions to improve alignment with the observed outcomes, reducing the systematic under- or overestimation of probabilities. Ideal calibration (dashed line): This represents perfect calibration, where the predicted probabilities perfectly match the actual probabilities. In an ideally calibrated model, the curve would coincide with the dashed line, indicating perfect agreement between predicted and observed probabilities. Mean absolute error (0.009): The calculated error value indicates the average discrepancy between the predicted probabilities and the actual outcomes. A lower value (such as 0.009 in this case) suggests good calibration, with minor deviations between predicted and actual probabilities. B = 1000 repetitions, boot: This suggests that bootstrapping was used to calculate confidence intervals and improve the stability of the calibration curve, based on 1000 resampling iterations.


overcoming the "black-box" limitation commonly associated with traditional machine learning algorithms. To optimize performance, we implemented early stopping, hyperparameter tuning, and class weighting (via the scale\_pos\_weight parameter) to improve model generalization under imbalanced conditions. The use of XGBoost facilitated high predictive performance through its advanced techniques, such as hyperparameter optimization and imbalance handling, while SHAP provided transparency, enabling clinicians to interpret individual model predictions and understand the underlying risk factors for amputation. The novelty of our approach lies in the seamless combination of the predictive power of XGBoost with the interpretability of SHAP, leading to more precise predictions and improved clinical insights.

Diabetic foot is a multifactorial syndrome requiring comprehensive evaluation from multiple perspectives [36]. In this context, we categorize the key influencing factors into four primary dimensions: wound characteristics, nutritional status, infection severity, and lower limb perfusion. The Wagner classification system is used to assess ulcer depth and the presence of osteomyelitis, with scores ranging from 0 to 5.









11




Figure 5 The weights of variable importance and the Beeswarm diagram drawn by SHapley Additive exPlanation to explain the three classification models. A: The weights of variable importance and the Beeswarm diagram drawn by SHapley Additive explanation (SHAP) to explain the nonamputation model; B: The weights of variable importance and the Beeswarm diagram drawn by SHAP to explain the Minor amputation model; C: The weights of variables importance and the Beeswarm diagram drawn by SHAP to explain the Major amputation model. The values in the bar chart represent the contribution value of each feature, the colors in SHAP value represent the level of correlation, and the left side of 0 represents negative correlation, while the right side represents positive correlation. SHAP: SHapley Additive exPlanation.

Feature selection was conducted using XGBoost, and the selected features were incorporated into SHAP analysis to determine their association with target outcomes. In the overall amputation model, the five most influential predictors identified were Wagner classification, albumin, CRP, PCT, and vascular interventional therapy. Notably, Wagner classification, CRP, and vascular interventional therapy were positively associated with the risk of amputation, while albumin was negatively associated. The model was refined to differentiate between minor and major amputation outcomes. In the minor amputation model, the top three predictors were Wagner classification, osteomyelitis, and vascular interventional therapy, all of which demonstrated significant correlations with the outcome. In the major amputation model, Wagner classification, wound size, and osteomyelitis were the strongest predictors, exhibiting significant positive correlations with amputation risk. In summary, our findings preliminarily suggest that a Wagner classification of 4/5 and the presence of osteomyelitis significantly increase the likelihood of amputation in DFU patients.

Numerous studies on the risk of DFU-associated amputation have consistently highlighted the reliability of the Wagner classification in predicting the likelihood of amputation [37,38]. For patients with diabetic foot presenting with gangrene at Wagner grade 4 or higher, amputation is often the most effective, life-saving intervention[27]. We observed a positive correlation between wound area and the risk of major amputation, which aligns with previous research demonstrating that larger wounds generally require more extensive surgical interventions, including major amputations [39,40]. Malnutrition is prevalent among patients with DFUs and significantly impacts prognosis[38]. The wound healing process requires an adequate supply of nutrients to the tissues, which may be compromised by impaired circulation and protein loss[41,42]. Low albumin levels reflect protein-energy malnutrition, which compromises collagen synthesis, angiogenesis, and fibroblast proliferation, thereby delaying tissue regeneration. Albumin also has anti-inflammatory and antioxidant properties. Reduced levels may reflect a heightened proinflammatory state, which contributes to persistent wound infection and impairs the resolution phase of wound healing. Our findings are consistent with prior clinical studies demonstrating that serum albumin is a strong prognostic marker for poor healing outcomes and major amputation in DFU cohorts[43]. This supports its role as not only a predictor in our model but also a potential target for nutritional intervention and monitoring in diabetic foot care. Prior studies have established that infection severity is a key predictor of amputation risk[44]. Our findings further support this, as elevated CRP levels were associated with an increased likelihood of major amputation. This association may be attributed to impaired immune response or compromised peripheral circulation [45]. Arterial stenosis or occlusion in the lower extremities can result in inadequate blood supply to local tissues, leading to foot gangrene. Thus, the severity of lower limb arterial stenosis serves as a critical determinant in assessing the necessity for amputation. It should also be emphasized that osteomyelitis is a strong predictor of amputation, but not the sole indication-particularly in cases of major amputation. Other clinical factors, such as severe ischemia, extensive soft tissue infection, or a poor overall prognosis, may also play a critical role in the decision to proceed with amputation.

To evaluate the clinical utility of the proposed model, we compared its decision-making capability with the Wagner classification system, a widely used clinical tool for assessing DFU severity and guiding treatment decisions. While Wagner grade is a strong and well-validated predictor of amputation risk, it is a 1D scale that does not account for key factors such as infection severity, ischemia, comorbidities, or nutritional status [46]. In contrast, our XGBoost-based model incorporated 29 multidimensional clinical features and provided individualized risk predictions supported by SHAP, allowing clinicians to interpret the contribution of each variable to a patient's predicted risk. For example, two patients with the same Wagner grade may receive different risk scores from our model due to differences in laboratory parameters (e.g., CRP or albumin), vascular status, or history of revascularization. This highlights the added value of the model in refining risk stratification beyond what is possible with Wagner grading alone. Therefore, our model has the potential to complement existing clinical tools by providing more nuanced, data-driven risk assessments that support personalized clinical decision-making.

In our study, we observed a minimal correlation between pre-admission antibiotic usage and the incidence of amputation. This lack of correlation may be attributed to the limited efficacy of antimicrobial therapy alone in the presence of osteomyelitis[47-49]. For acute diabetic foot infections, surgical incision and abscess drainage are essential components of treatment and should be performed in conjunction with systemic antibiotic therapy [50,51]. Cultures from wound biopsy or curetted necrotic tissue remain the preferred methods for identifying the causative pathogens[52]. Osteomyelitis plays a critical role in the management of diabetic foot infections, with surveys indicating that approximately 50% of patients with osteomyelitis-related DFUs undergo amputation[53]. Consequently, early debridement in patients with diabetic foot infections suspected of osteomyelitis may expedite wound healing.

Our findings indicated that vascular intervention was positively associated with minor amputation risk but showed no significant correlation in the major amputation model. This discrepancy may reflect fundamental differences in pathophysiological mechanisms and patient characteristics between the two groups. Patients undergoing major amputation often present with advanced peripheral arterial disease and critical limb ischemia, where tissue necrosis is already extensive. In such cases, vascular interventions, if performed, typically represent salvage attempts rather than proactive measures, and may not be sufficient to prevent limb loss. Consequently, the presence of vascular intervention in this group may serve as a surrogate marker for disease severity rather than therapeutic success, thereby diminishing its predictive utility. In contrast, in the minor amputation group, vascular interventions are more likely to be applied earlier in the disease trajectory, when ischemia is less severe and tissues are still viable. Under these conditions, revascularization may serve as an effective modifying factor, helping to preserve limb integrity and prevent progression to major amputation. This may explain its positive association with minor amputation outcomes. Additionally, differences in timing, patient selection criteria, and clinical decision-making processes may further account for the observed variability in the relevance of vascular intervention between the two models [54,55].

Early identification and management of risk factors associated with diabetic foot can significantly influence surgical decision-making [56-58]. In clinical diagnosis, it is crucial to enhance regular foot examinations, promptly identify highrisk patients, and initiate vascular interventional therapy at the earliest opportunity for those experiencing lower limb ischemia. In clinical treatment, continuous wound evaluation is imperative to monitor changes in wound characteristics, assess infection status, and determine the efficacy of therapeutic interventions. Additionally, it is essential to closely monitor blood glucose fluctuations and address hypoproteinemia. Compared to patients with mild DFUs (Wagner grades 1/2), those with moderate to severe ulcers (Wagner grades 3-5) typically present with deeper lesions, a greater demand for nutrients (such as protein) for wound healing, and exhibit a more compromised nutritional status[59]. Our XGBoost-SHAP predictive model combines high accuracy with clinical interpretability, making it suitable for real-world use. It can support early identification of high-risk patients and guide individualized care strategies. Importantly, it can be integrated into clinical decision support systems within EHRs to provide patient-specific risk estimates and SHAP-based explanations, facilitating informed and timely clinical decision-making.

Our study had several limitations. Firstly, although we used the efficient XGBoost algorithm to predict the probability of amputation in diabetic foot, we did not compare its predictive accuracy with that of traditional machine learning methods, which limits the robustness of our findings. Moreover, the retrospective nature of the study and the clinical data derived primarily from EHRs, described and organized by clinicians, introduce the potential for subjective variability in ulcer description and grading. Secondly, the decision to amputate is influenced by multiple factors. Patients with Wagner grade 4/5 ulcers who had gangrene but did not undergo amputation may reflect differences in clinical judgment, patient preferences, or comorbidities, with decisions influenced by factors such as conservative treatment, surgical risk, or refusal of surgery. Nonmedical factors, such as limited financial resources, lack of social support, or patient refusal of limbsalvage interventions, can influence the decision to perform major amputations, and may introduce confounding data when evaluating medically driven risk factors. Prospective studies should incorporate standardized assessments of nonclinical factors. Doing so would help distinguish between medically indicated amputations and those driven by extrinsic constraints, thereby improving the precision and generalizability of amputation risk models. Thirdly, the primary outcome focused on amputation events. However, we acknowledge that some patients in the non-amputation group may have had unhealed wounds due to factors such as poor overall health status, severe ischemia, or limited treatment tolerance, despite not undergoing surgery. Due to the retrospective nature of our dataset and limitations in long-term follow-up documentation, we were unable to consistently capture wound healing status across the entire cohort. Future prospective studies should incorporate systematic tracking of wound healing outcomes, as wound closure represents a critical clinical endpoint. This would enable a more nuanced evaluation of treatment efficacy and patient trajectories beyond the binary outcome of amputation. Fourthly, the retrospective, single-center design may have introduced selection bias and limit the generalization of the model, as clinical practices, patient characteristics, and data availability can vary across settings. To improve external validity, future work should include multicenter validation across diverse populations, prospective data collection to reduce bias, external validation with recalibration, and the development of adaptable or region-specific models. These steps will enhance the robustness, clinical relevance, and realworld applicability of the model.

# CONCLUSION

We developed a multi-class classification model using the XGBoost algorithm to predict the risk of amputation among patients with DFUs during hospitalization. We ensured the interpretability of the model outcomes through feature selection and elucidation of significant variables. The results demonstrated that this machine learning model exhibited superior predictive performance, providing clinicians with comprehensive insights into each patient's risk factors and their respective contributions, thereby supporting timely interventions to reduce the incidence of major amputations.

# **FOOTNOTES**

Author contributions: Gao L conducted experiments and guided the writing of the manuscript; Liu ZX collected and analyzed the data; Wang JN is the corresponding author of this manuscript; Wang JN designed the experimental program and chaired the seminar. This manuscript has been read and approved by all the co-authors. Gao L and Liu ZX contributed equally to this work and they are co-first

Institutional review board statement: This study was performed in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki and approved by the Ethical Review Committee of Beijing Shijitan Hospital, Capital Medical University, No. IIT2025-049-001.

**Informed consent statement:** This study was a retrospective analysis of anonymized clinical data. Ethical approval was obtained from the Institutional Review Board, and the requirement for informed consent was waived.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

Data sharing statement: The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

**ORCID number:** Lei Gao 0000-0003-1009-9529; Zi-Xuan Liu 0009-0002-9906-6570; Jiang-Ning Wang 0009-0004-7201-8688.

S-Editor: Qu XL L-Editor: Filipodia P-Editor: Zhang XD

#### REFERENCES

- Gong H, Ren Y, Li Z, Zha P, Bista R, Li Y, Chen D, Gao Y, Chen L, Ran X, Wang C. Clinical characteristics and risk factors of lower extremity amputation in the diabetic inpatients with foot ulcers. Front Endocrinol (Lausanne) 2023; 14: 1144806 [PMID: 37065766 DOI: 10.3389/fendo.2023.1144806] [FullText]
- 2 Rathnayake A, Saboo A, Malabu UH, Falhammar H. Lower extremity amputations and long-term outcomes in diabetic foot ulcers: A systematic review. World J Diabetes 2020; 11: 391-399 [PMID: 32994867 DOI: 10.4239/wjd.v11.i9.391] [FullText]
- Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med 2017; 376: 2367-2375 [PMID: 28614678 DOI: 10.1056/NEJMra1615439] [FullText]
- Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM. Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers. Diabetes Care 2018; 41: 645-652 [PMID: 29559450 DOI: 10.2337/dc17-1836] [FullText]
- Dutra LMA, Melo MC, Moura MC, Leme LAP, De Carvalho MR, Mascarenhas AN, Novaes MRCG. Prognosis of the outcome of severe



- diabetic foot ulcers with multidisciplinary care. J Multidiscip Healthc 2019; 12: 349-359 [PMID: 31118658 DOI: 10.2147/JMDH.S194969]
- Jupiter DC, Thorud JC, Buckley CJ, Shibuya N. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From 6 ulceration to death, a systematic review. Int Wound J 2016; 13: 892-903 [PMID: 25601358 DOI: 10.1111/iwj.12404] [FullText]
- 7 Luo Y, Liu C, Li C, Jin M, Pi L, Jin Z. The incidence of lower extremity amputation and its associated risk factors in patients with diabetic foot ulcers: A meta-analysis. Int Wound J 2024; 21: e14931 [PMID: 38972836 DOI: 10.1111/iwj.14931] [FullText]
- Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and 8 ischemia to risk of amputation. Diabetes Care 1998; 21: 855-859 [PMID: 9589255 DOI: 10.2337/diacare.21.5.855] [FullText]
- 9 Meloni M, Morosetti D, Giurato L, Stefanini M, Loreni G, Doddi M, Panunzi A, Bellia A, Gandini R, Brocco E, Lazaro-Martinez JL, Lauro D, Uccioli L. Foot Revascularization Avoids Major Amputation in Persons with Diabetes and Ischaemic Foot Ulcers. J Clin Med 2021; 10: 3977 [PMID: 34501432 DOI: 10.3390/jcm10173977] [FullText]
- Ugwu E, Adeleye O, Gezawa I, Okpe I, Enamino M, Ezeani I. Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study. J Foot Ankle Res 2019; 12: 34 [PMID: 31223342 DOI: 10.1186/s13047-019-0345-y] [FullText]
- Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC. International consensus and practical guidelines on the 11 management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2000; 16 Suppl 1: S84-S92 [PMID: 11054895 DOI: 10.1002/1520-7560(200009/10)16:1+<::aid-dmrr113>3.0.co;2-s] [FullText]
- 12 Apelqvist J, Bakker K, van Houtum WH, Schaper NC; International Working Group on the Diabetic Foot (IWGDF) Editorial Board. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2008; 24 Suppl 1: S181-S187 [PMID: 18442189] DOI: 10.1002/dmrr.8481 [FullText]
- Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer classification systems: the 13 Wagner and the University of Texas wound classification systems. Diabetes Care 2001; 24: 84-88 [PMID: 11194247 DOI: 10.2337/diacare.24.1.84] [FullText]
- Hicks CW, Canner JK, Mathioudakis N, Sherman R, Malas MB, Black JH 3rd, Abularrage CJ. The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification independently predicts wound healing in diabetic foot ulcers. J Vasc Surg 2018; 68: 1096-1103 [PMID: 29622357 DOI: 10.1016/j.jvs.2017.12.079] [FullText]
- 15 Haug CJ, Drazen JM. Artificial Intelligence and Machine Learning in Clinical Medicine, 2023. N Engl J Med 2023; 388: 1201-1208 [PMID: 36988595 DOI: 10.1056/NEJMra2302038] [FullText]
- Wu PY, Yu YL, Zhao WR, Zhou B. Identifying and Validating Extracellular Matrix-Related Gene CTSH in Diabetic Foot Ulcer Using 16 Bioinformatics and Machine Learning. J Inflamm Res 2024; 17: 5871-5887 [PMID: 39228680 DOI: 10.2147/JIR.S467507] [FullText]
- Howard T, Ahluwalia R, Papanas N. The Advent of Artificial Intelligence in Diabetic Foot Medicine: A New Horizon, a New Order, or a 17 False Dawn? Int J Low Extrem Wounds 2023; 22: 635-640 [PMID: 34488463 DOI: 10.1177/15347346211041866] [FullText]
- Kuo CY, Liu CW, Lai CH, Kang JH, Tseng SH, Su EC. Prediction of robotic neurorehabilitation functional ambulatory outcome in patients 18 with neurological disorders. J Neuroeng Rehabil 2021; 18: 174 [PMID: 34922571 DOI: 10.1186/s12984-021-00965-6] [FullText]
- Rudin C. Stop Explaining Black Box Machine Learning Models for High Stakes Decisions and Use Interpretable Models Instead. Nat Mach 19 Intell 2019; 1: 206-215 [PMID: 35603010 DOI: 10.1038/s42256-019-0048-x] [FullText]
- 20 Xie P, Li Y, Deng B, Du C, Rui S, Deng W, Wang M, Boey J, Armstrong DG, Ma Y, Deng W. An explainable machine learning model for predicting in-hospital amputation rate of patients with diabetic foot ulcer. Int Wound J 2022; 19: 910-918 [PMID: 34520110 DOI: 10.1111/iwj.13691] [FullText]
- Jiang A, Li J, Wang L, Zha W, Lin Y, Zhao J, Fang Z, Shen G. Multi-feature, Chinese-Western medicine-integrated prediction model for 21 diabetic peripheral neuropathy based on machine learning and SHAP. Diabetes Metab Res Rev 2024; 40: e3801 [PMID: 38616511 DOI: 10.1002/dmrr.3801] [FullText]
- Liu J, Wu J, Liu S, Li M, Hu K, Li K. Predicting mortality of patients with acute kidney injury in the ICU using XGBoost model. PLoS One 22 2021; 16: e0246306 [PMID: 33539390 DOI: 10.1371/journal.pone.0246306] [FullText]
- Hou N, Li M, He L, Xie B, Wang L, Zhang R, Yu Y, Sun X, Pan Z, Wang K. Predicting 30-days mortality for MIMIC-III patients with sepsis-23 3: a machine learning approach using XGboost. J Transl Med 2020; 18: 462 [PMID: 33287854 DOI: 10.1186/s12967-020-02620-5] [FullText]
- 24 Hu C, Li L, Huang W, Wu T, Xu Q, Liu J, Hu B. Interpretable Machine Learning for Early Prediction of Prognosis in Sepsis: A Discovery and Validation Study. Infect Dis Ther 2022; 11: 1117-1132 [PMID: 35399146 DOI: 10.1007/s40121-022-00628-6] [FullText]
- Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Fitridge R, Game F, Monteiro-Soares M, Senneville E; IWGDF Editorial Board. Practical 25 guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev 2024; 40: e3657 [PMID: 37243927 DOI: 10.1002/dmrr.3657] [FullText]
- Lopes GSG, Landeiro MJL, Maciel T, Sousa MRMGC. Clinical practice guidelines of foot care practice for patients with type 2 diabetes: A scoping review using self-care model. Contemp Nurse 2024; 60: 516-536 [PMID: 38831701 DOI: 10.1080/10376178.2024.2362289] [Full
- Yang L, Rong GC, Wu QN. Diabetic foot ulcer: Challenges and future. World J Diabetes 2022; 13: 1014-1034 [PMID: 36578870 DOI: 27 10.4239/wjd.v13.i12.1014] [FullText]
- Méndez Barrera JA, Rocha Guzmán S, Hierro Cascajares E, Garabedian EK, Fuleihan RL, Sullivan KE, Lugo Reyes SO. Who's your data? Primary immune deficiency differential diagnosis prediction via machine learning and data mining of the USIDNET registry. Clin Immunol 2023; **255**: 109759 [PMID: 37678719 DOI: 10.1016/j.clim.2023.109759] [FullText]
- 29 Nguyen H, Agu E, Tulu B, Strong D, Mombini H, Pedersen P, Lindsay C, Dunn R, Loretz L. Machine learning models for synthesizing actionable care decisions on lower extremity wounds. Smart Health (Amst) 2020; 18: 100139 [PMID: 33299924 DOI: 10.1016/j.smhl.2020.100139] [FullText]
- Wang S, Wang J, Zhu MX, Tan Q. Machine learning for the prediction of minor amputation in University of Texas grade 3 diabetic foot 30 ulcers. PLoS One 2022; 17: e0278445 [PMID: 36472981 DOI: 10.1371/journal.pone.0278445] [FullText]
- Al-Garaawi N, Ebsim R, Alharan AFH, Yap MH. Diabetic foot ulcer classification using mapped binary patterns and convolutional neural 31 networks. Comput Biol Med 2022; 140: 105055 [PMID: 34839183 DOI: 10.1016/j.compbiomed.2021.105055] [FullText]
- Ma YN, Zhang LX, Hu YY, Shi TL. Nomogram Model for Predicting the Risk of Multidrug-Resistant Bacteria Infection in Diabetic Foot 32

15



- Patients. Infect Drug Resist 2021; 14: 627-637 [PMID: 33633458 DOI: 10.2147/IDR.S287852] [FullText]
- Deng L, Xie P, Chen Y, Rui S, Yang C, Deng B, Wang M, Armstrong DG, Ma Y, Deng W. Impact of acute hyperglycemic crisis episode on 33 survival in individuals with diabetic foot ulcer using a machine learning approach. Front Endocrinol (Lausanne) 2022; 13: 974063 [PMID: 36093085 DOI: 10.3389/fendo.2022.974063] [FullText]
- 34 Prabha A, Yadav J, Rani A, Singh V. Design of intelligent diabetes mellitus detection system using hybrid feature selection based XGBoost classifier. Comput Biol Med 2021; 136: 104664 [PMID: 34329866 DOI: 10.1016/j.compbiomed.2021.104664] [FullText]
- Jodheea-Jutton A, Hindocha S, Bhaw-Luximon A. Health economics of diabetic foot ulcer and recent trends to accelerate treatment. Foot 35 (Edinb) 2022; **52**: 101909 [PMID: 36049265 DOI: 10.1016/j.foot.2022.101909] [FullText]
- Demirkol D, Aktaş Ş, Özcan T, Tannier X, Selçukcan Erol Ç. Analysis of risk factors for amputation in patients with diabetic foot ulcers: a 36 cohort study from a tertiary center. Acta Orthop Traumatol Turc 2022; 56: 333-339 [PMID: 36250877 DOI: 10.5152/j.aott.2022.22052] [Full
- 37 Vera-Cruz PN, Palmes PP, Tonogan L, Troncillo AH. Comparison of WIFi, University of Texas and Wagner Classification Systems as Major Amputation Predictors for Admitted Diabetic Foot Patients: A Prospective Cohort Study. Malays Orthop J 2020; 14: 114-123 [PMID: 33403071 DOI: 10.5704/MOJ.2011.018] [FullText]
- Lauwers P, Dirinck E, Van Bouwel S, Verrijken A, Van Dessel K, Van Gils C, Sels M, Peiffer F, Van Schil P, De Block C, Hendriks J. 38 Malnutrition and its relation with diabetic foot ulcer severity and outcome: a review. Acta Clin Belg 2022; 77: 79-85 [PMID: 32727304 DOI: 10.1080/17843286.2020.1800315] [FullText]
- Sun JH, Tsai JS, Huang CH, Lin CH, Yang HM, Chan YS, Hsieh SH, Hsu BR, Huang YY. Risk factors for lower extremity amputation in diabetic foot disease categorized by Wagner classification. Diabetes Res Clin Pract 2012; 95: 358-363 [PMID: 22115502 DOI: 10.1016/j.diabres.2011.10.034] [FullText]
- 40 Mansoor Z, Modaweb A. Predicting Amputation in Patients With Diabetic Foot Ulcers: A Systematic Review. Cureus 2022; 14: e27245 [PMID: 36035032 DOI: 10.7759/cureus.27245] [FullText]
- Martínez García RM, Fuentes Chacón RM, Lorenzo Mora AM, Ortega Anta RM. [Nutrition in the prevention and healing of chronic wounds. 41 Importance in improving the diabetic foot]. Nutr Hosp 2021; 38: 60-63 [PMID: 34323091 DOI: 10.20960/nh.03800] [FullText]
- Litchford MD. Nutritional Issues in The Patient with Diabetes and Foot Ulcers. In: Bowker JH, Pfeifer MA, editors. Levin and O'Neal's The 42 Diabetic Foot (Seventh Edition). Mosby, 2008: 199-217 [DOI: 10.1016/b978-0-323-04145-4.50015-6] [FullText]
- 43 Cheng P, Dong Y, Hu Z, Huang S, Cao X, Wang P, Xu H, Zhu J, Tang B. Biomarker Prediction of Postoperative Healing of Diabetic Foot Ulcers: A Retrospective Observational Study of Serum Albumin. J Wound Ostomy Continence Nurs 2021; 48: 339-344 [PMID: 34186553] DOI: 10.1097/WON.000000000000780] [FullText]
- 44 Metineren H, Dülgeroğlu TC. Comparison of the Neutrophil/Lymphocyte Ratio and C-Reactive Protein Levels in Patients With Amputation for Diabetic Foot Ulcers. Int J Low Extrem Wounds 2017; 16: 23-28 [PMID: 28682678 DOI: 10.1177/1534734617696729] [FullText]
- Cervantes-García E, Salazar-Schettino PM. Clinical and surgical characteristics of infected diabetic foot ulcers in a tertiary hospital of 45 Mexico. Diabet Foot Ankle 2017; 8: 1367210 [PMID: 28904744 DOI: 10.1080/2000625X.2017.1367210] [FullText]
- Jeon BJ, Choi HJ, Kang JS, Tak MS, Park ES. Comparison of five systems of classification of diabetic foot ulcers and predictive factors for 46 amputation. Int Wound J 2017; 14: 537-545 [PMID: 27723246 DOI: 10.1111/iwj.12642] [FullText]
- Chatzipapas C, Karaglani M, Papanas N, Tilkeridis K, Drosos GI. Local Antibiotic Delivery Systems in Diabetic Foot Osteomyelitis: A Brief 47 Review. Rev Diabet Stud 2021; 17: 75-81 [PMID: 34852898 DOI: 10.1900/RDS.2021.17.75] [FullText]
- Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbančič-48 Rovan V, Peters EJG; International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36 Suppl 1: e3280 [PMID: 32176444 DOI: 10.1002/dmrr.3280] [FullText]
- 49 Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 2017; 6: CD011038 [PMID: 28613416 DOI: 10.1002/14651858.CD011038.pub2] [FullText]
- Truong DH, Bedimo R, Malone M, Wukich DK, Oz OK, Killeen AL, Lavery LA. Meta-Analysis: Outcomes of Surgical and Medical Management of Diabetic Foot Osteomyelitis. Open Forum Infect Dis 2022; 9: ofac407 [PMID: 36147596 DOI: 10.1093/ofid/ofac407] [Full Text1
- Peters EJG, Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, Urbančič-Rovan 51 V, Van Asten SA. Interventions in the management of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev 2020; 36 Suppl 1: e3282 [PMID: 32176437 DOI: 10.1002/dmrr.3282] [FullText]
- Lam K, van Asten SA, Nguyen T, La Fontaine J, Lavery LA. Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review. Clin Infect Dis 2016; 63: 944-948 [PMID: 27369321 DOI: 10.1093/cid/ciw445] [FullText]
- Kim SY, Kim TH, Choi JY, Kwon YJ, Choi DH, Kim KC, Kim MJ, Hwang HK, Lee KB. Predictors for Amputation in Patients with Diabetic 53 Foot Wound. Vasc Specialist Int 2018; 34: 109-116 [PMID: 30671420 DOI: 10.5758/vsi.2018.34.4.109] [FullText]
- 54 Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, Caminiti M, Curci V, Lupattelli T, Morabito A. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg 2006; 32: 484-490 [PMID: 16730466 DOI: 10.1016/j.ejvs.2006.03.006] [FullText]
- Uccioli L, Gandini R, Giurato L, Fabiano S, Pampana E, Spallone V, Vainieri E, Simonetti G. Long-term outcomes of diabetic patients with 55 critical limb ischemia followed in a tertiary referral diabetic foot clinic. Diabetes Care 2010; 33: 977-982 [PMID: 20200304 DOI: 10.2337/dc09-0831] [FullText]
- Rismayanti IDA, Nursalam N, Farida VN, Dewi NWS, Utami R, Aris A, Agustini NLPIB. Early detection to prevent foot ulceration among 56 type 2 diabetes mellitus patient: A multi-intervention review. J Public Health Res 2022; 11: 2752 [PMID: 35315261 DOI: 10.4081/jphr.2022.2752] [FullText]
- Serban D, Papanas N, Dascalu AM, Kempler P, Raz I, Rizvi AA, Rizzo M, Tudor C, Silviu Tudosie M, Tanasescu D, Pantea Stoian A, Gouveri E, Ovidiu Costea D. Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets. Int J Low Extrem Wounds 2024; 23: 205-216 [PMID: 34791913 DOI: 10.1177/15347346211057742] [FullText]
- Shojaiefard A, Khorgami Z, Larijani B. Independent risk factors for amputation in diabetic foot. Int J Diabetes Dev Ctries 2008; 28: 32-37 [PMID: 19902045 DOI: 10.4103/0973-3930.43096] [FullText]



59 Lavery LA, Ryan EC, Ahn J, Crisologo PA, Oz OK, La Fontaine J, Wukich DK. The Infected Diabetic Foot: Re-evaluating the Infectious Diseases Society of America Diabetic Foot Infection Classification. Clin Infect Dis 2020; 70: 1573-1579 [PMID: 31179491 DOI: 10.1093/cid/ciz489] [FullText]

17



# Published by Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

E-mail: office@baishideng.com

Help Desk: https://www.f6publishing.com/helpdesk

https://www.wjgnet.com

